{"id":"NCT01901146","sponsor":"Amgen","briefTitle":"Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer","officialTitle":"A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-04-29","primaryCompletion":"2016-05-05","completion":"2017-01-27","firstPosted":"2013-07-17","resultsPosted":"2019-08-07","lastUpdate":"2019-08-07"},"enrollment":725,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"ABP 980","otherNames":[]},{"type":"DRUG","name":"Trastuzumab","otherNames":["HerceptinÂ®"]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"PROCEDURE","name":"Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection","otherNames":[]}],"arms":[{"label":"ABP 980","type":"EXPERIMENTAL"},{"label":"Trastuzumab","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this research study is to compare the effectiveness and safety of ABP 980 against trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.","primaryOutcome":{"measure":"Percentage of Participants With a Pathologic Complete Response","timeFrame":"3 to 7 weeks after the last dose of study drug in the neoadjuvant phase","effectByArm":[{"arm":"ABP 980","deltaMin":48,"sd":null},{"arm":"Trastuzumab","deltaMin":40.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0508"},{"comp":"OG000 vs OG001","p":"0.0430"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":17},"locations":{"siteCount":98,"countries":["Belarus","Brazil","Bulgaria","Canada","Chile","Germany","Greece","Hungary","Italy","Mexico","Poland","Romania","Russia","Serbia","South Africa","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["31927716","29880292"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":364},"commonTop":["Arthralgia","Asthenia","Neutropenia","Anaemia","Neuropathy peripheral"]}}